Back

Cardioprotective effect of empagliflozin in acute myocardial infarction: the role of ketone bodies availability.

28 August 2022 (16:10 - 16:20)
Organised by:
Congress Presentation Part of: What’s new on lipids and diabetes in acute coronary syndrome Treatment ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Juan Jose Badimon

Icahn School of Medicine at Mount Sinai, New York City (United States of America)

5 More presentations in this session

Presentation thumbnail
Lipoprotein(a) and the effect of alirocumab on coronary and non-coronary revascularization following acute coronary syndrome
Professor P. Steg (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Proprotein convertase subtilisin/kexin type 9 (PCSK9), platelet activation and interaction with the vascular endothelium: the impact of PCSK9 inhibition with evolocumab in acute coronary syndrome
Doctor E. Ziogos (Baltimore, US)
Abstract Slides Video
Presentation thumbnail
Quality matters: low-density lipoprotein electronegativity but not quantity determines mortality risk in acute coronary syndromes
Doctor S. Kraler (Bern, CH)
Abstract Slides Video
Presentation thumbnail
Glycated haemoglobin and the association with long-term survival among patients evaluated for stable angina - a prospective Norwegian cohort
Doctor G. Svingen (Bergen, NO)
Abstract Slides Video
Presentation thumbnail
Impact of chronic GLP-1 receptor agonist and SGLT-2 inhibitor therapy on in-hospital outcomes of patients with diabetes mellitus hospitalized with acute myocardial infarction.
Doctor F. Trombara (Milan, IT)
Abstract Slides Video

Access the full session

Session thumbnail
What’s new on lipids and diabetes in acute coronary syndrome

The Event

Event poster

ESC Congress 2022

28 August 2022 16:10 CET
You may be interested in
thumbnail
Congress Presentation
Mechanistic insights of SGLT2 inhibitors effectiveness
thumbnail
Congress Presentation
Is SiGLT2i the treatment for diabetic cardiomyopathy?
thumbnail
Congress Presentation
SGLT2 inhibitors and heart failure: mechanisms and clinical implications

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources